Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (351-360 of 483) with videos related to

Pageof 49
Sort By:
Scientific Reports|March 29, 2026
Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samplesFranz Josef Gassner, Gabriel Rinnerthaler, Vanessa Castagnaviz, et al.
Cancers|February 25, 2023
The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML CellsLaura Urwanisch, Michael Stefan Unger, Helene Sieberer, et al.
Wiener Klinische Wochenschrift|March 3, 2012
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]Ingrid Pabinger, Günther Gastl, Michael Steurer, et al.
Annals of Hematology|June 22, 2014
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Sonja Burgstaller, Michael Girschikofsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myelomaHeinz Ludwig, Luisa Viterbo, Richard Greil, et al.
The Journal of Pathology|March 31, 2015
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocationOlaf Merkel, Frank Hamacher, Robert Griessl, et al.
Blood Advances|February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 studyJason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Journal for Immunotherapy of Cancer|October 22, 2021
Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinomaVictoria M Leb-Reichl, Melanie Kienzl, Anna Kaufmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2022
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trialGuillaume Lingas, Nadège Néant, Alexandre Gaymard, et al.
Pageof 49

Showing results (351-360 of 483) with videos related to

Sort By:
Pageof 49
Scientific Reports|March 29, 2026
Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samplesFranz Josef Gassner, Gabriel Rinnerthaler, Vanessa Castagnaviz, et al.
Cancers|February 25, 2023
The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML CellsLaura Urwanisch, Michael Stefan Unger, Helene Sieberer, et al.
Wiener Klinische Wochenschrift|March 3, 2012
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]Ingrid Pabinger, Günther Gastl, Michael Steurer, et al.
Annals of Hematology|June 22, 2014
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Sonja Burgstaller, Michael Girschikofsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myelomaHeinz Ludwig, Luisa Viterbo, Richard Greil, et al.
The Journal of Pathology|March 31, 2015
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocationOlaf Merkel, Frank Hamacher, Robert Griessl, et al.
Blood Advances|February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 studyJason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Journal for Immunotherapy of Cancer|October 22, 2021
Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinomaVictoria M Leb-Reichl, Melanie Kienzl, Anna Kaufmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2022
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trialGuillaume Lingas, Nadège Néant, Alexandre Gaymard, et al.
Pageof 49